Only in Titles

Search results for: Virus

paperclip

#32770873   // To Up

[Social considerations affecting acceptance of HPV vaccination in Colombia. A systematic review].

To identify social factors influencing the acceptance of human papilloma virus (HPV) vaccination in the Colombian population before and after the unexpected and poorly defined event of unknown etiology which occurred in 2014.
Francisco Palencia-Sánchez, Sandra Johanna Echeverry-Coral

2752 related Products with: [Social considerations affecting acceptance of HPV vaccination in Colombia. A systematic review].

25 G100 μg100μg100 μg100ug100 μg0.1 mg100 μg1 Set100 μg1 Set1 Set

Related Pathways

paperclip

#32770858   2020/08/08 To Up

Updated information on new coronavirus disease 2019 occurrence, drugs, and prediction of a potential receptor.

The new coronavirus (COVID-19) was first reported in Wuhan in China, on 31 December 2019. COVID-19 is a new virus from the family of coronaviruses that can cause symptoms ranging from a simple cold to pneumonia. The virus is thought to bind to the angiotensin-converting enzyme 2, as a well-known mechanism to enter the cell. It then transfers its DNA to the host in which the virus replicates the DNA. The viral infection leads to severe lack of oxygen, lung oxidative stress because of reactive oxygen species generation, and overactivation of the immune system by activating immune mediators. The purpose of this review is to elaborate on the more precise mechanism(s) to manage the treatment of the disease. Regarding the mechanisms of the virus action, the suggested pharmacological and nutritional regimens have been described.
Forouzan Khodaei, Anam Ahsan, Mostafa Chamanifard, Mohammad Javad Zamiri, Mohammad Mehdi Ommati

2746 related Products with: Updated information on new coronavirus disease 2019 occurrence, drugs, and prediction of a potential receptor.

1 ml1000 100ug50 ug 100ug5mg100ul100.00 ul100ug100ul

Related Pathways

paperclip

#32770836   2020/08/08 To Up

Immune-mobilising monoclonal T cell receptors mediate specific and rapid elimination of Hepatitis B-infected cells.

New therapies for chronic HBV infection are urgently needed due to viral integration, persistence of viral antigen expression, inadequate HBV-specific immune responses and treatment regimens that require life-long adherence to suppress the virus. Immune mobilising monoclonal T cell receptors Against Virus (ImmTAV ) molecules represent a novel therapeutic strategy combining an affinity-enhanced T cell receptor with an anti-CD3 T cell-activating moiety. This bispecific fusion protein redirects T cells to specifically lyse infected cells expressing the target virus-derived peptides presented by human leukocyte antigen (HLA).
Joannah R Fergusson, Zoë Wallace, Mary M Connolly, Amanda P Woon, Richard J Suckling, Dominic W Hine, Claire Barber, Wilawan Bunjobpol, Beak-San Choi, Sara Crespillo, Marcin Dembek, Nele Dieckmann, Jose Donoso, Luis F Godinho, Tressan Grant, Dawn Howe, Michelle L McCully, Carole Perot, Anshuk Sarkar, Florian U Seifert, Praveen K Singh, Kerstin A Stegmann, Bethany Turner, Anil Verma, Andrew Walker, Sarah Leonard, Mala K Maini, Katrin Wiederhold, Lucy Dorrell, Ruth Simmons, Andrew Knox

1043 related Products with: Immune-mobilising monoclonal T cell receptors mediate specific and rapid elimination of Hepatitis B-infected cells.

100 µg100.00 ug100 µg100.00 ug1 mg100.00 ug100ul1.00 flask100ul50ml0.2 mg

Related Pathways

paperclip

#32770831   2020/08/08 To Up

Cannabidivarin for HIV-associated neuropathic pain - a randomized, blinded, controlled clinical trial.

The human immunodeficiency virus (HIV) remains a major burden to the health care system and neuropathic pain is the most common neurological complication of HIV infection. Since current treatment strategies often lack satisfying pain relief, cannabinoids are discussed as a new option. We investigated cannabidivarin as treatment for HIV-associated neuropathic pain. We conducted a randomized, double-blind, placebo-controlled cross-over study. Patients underwent two successive treatment phases (4 weeks each) and were treated with cannabidivarin (400mg/d) or placebo in a randomized order. A 3-week wash-out phase was designed to eliminate potential carry-over effects. Patients were followed up for 3 weeks after the end of the second treatment phase. The primary endpoint was pain intensity on an 11-point numeric rating scale, recorded in a diary. Secondary endpoints were additional pain medication, pain characteristics and quality of life. We included 32 patients. The mean pain intensity under cannabidivarin was 0.62 points higher compared to placebo (p=0.16; 95% CI -0.27 to 1.51). Cannabidivarin did not influence the amount of additional pain medication, pain characteristics or quality of life. The incidence of adverse events was similar during both treatments. No suspected unexpected adverse reactions occurred during either treatment. Cannabidivarin was safe but failed to reduce neuropathic pain in HIV-patients. This may be explained by a lack of cannabinoid receptor activation, as indicated by preclinical experiments. Although a larger patient number might be desirable, we would not expect a change in the conclusions since the present differences are far from statistical significance. Therefore, we would currently not consider CBDV as a clinically meaningful treatment option for neuropathic pain.
Luca Eibach, Simone Scheffel, Madeleine Cardebring, Marie Lettau, M Özgür Celik, Andreas Morguet, Robert Roehle, Christoph Stein

2169 related Products with: Cannabidivarin for HIV-associated neuropathic pain - a randomized, blinded, controlled clinical trial.

200 mg1,000 tests

Related Pathways

paperclip

#32770825   2020/08/08 To Up

Bacterial co-infections with SARS-CoV-2.

The pandemic coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has affected millions of people worldwide. To date, there are no proven effective therapies for this virus. Efforts made to develop antiviral strategies for the treatment of COVID-19 are underway. Respiratory viral infections, such as influenza, predispose patients to co-infections and these lead to increased disease severity and mortality. Numerous types of antibiotics such as azithromycin have been employed for the prevention and treatment of bacterial co-infection and secondary bacterial infections in patients with a viral respiratory infection (e.g., SARS-CoV-2). Although antibiotics do not directly affect SARS-CoV-2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co-infection rather than virus itself. To date, a considerable number of bacterial strains have been resistant to various antibiotics such as azithromycin, and the overuse could render those or other antibiotics even less effective. Therefore, bacterial co-infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID-19. Also, the antibiotic-resistant as a result of overusing must be considered. In this review, we will summarize the bacterial co-infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID-19.
Rasoul Mirzaei, Pedram Goodarzi, Muhammad Asadi, Ayda Soltani, Hussain Ali Abraham Aljanabi, Ali Salimi Jeda, Shirin Dashtbin, Saba Jalalifar, Rokhsareh Mohammadzadeh, Ali Teimoori, Kamran Tari, Mehdi Salari, Sima Ghiasvand, Sima Kazemi, Rasoul Yousefimashouf, Hossein Keyvani, Sajad Karampoor

1569 related Products with: Bacterial co-infections with SARS-CoV-2.

100ul1000100 ug/vial96T200 500100500100 µg0.2 mg

Related Pathways

paperclip

#32770814   2020/08/08 To Up

Is it necessary to evaluate urinary tract infection in children with lower respiratory tract infection?

Although the incidence of urinary tract infection (UTI) in children with lower respiratory tract infection (LRTI) has been reported as 3.1-10.0%, the exact concomitant prevalence is questionable. Here, we evaluated the prevalence and related risk factors of UTI associated with LRTI in children under 36 months of age.
Jeong Min Kim, Ja Wook Koo, Hyo-Bin Kim

1116 related Products with: Is it necessary to evaluate urinary tract infection in children with lower respiratory tract infection?

96 tests96 tests100 μg100ug Lyophilized100ug Lyophilized100ug Lyophilized10

Related Pathways

paperclip

#32770770   2020/08/08 To Up

Efficacy of fiberoptic bronchoscopy and bronchoalveolar lavage in childhood-onset, complicated plastic bronchitis.

Plastic bronchitis (PB) is a rare, variable, and potentially fatal disease. This study aimed to assess the efficacy of fiberoptic bronchoscopy (FOB) and bronchoalveolar lavage (BAL) in treating children with PB.
Li Wang, Wang Wang, Jing-Min Sun, Shen-Wang Ni, Jun-Li Ding, Yu-Lin Zhu, Sheng-Gang Ding

1472 related Products with: Efficacy of fiberoptic bronchoscopy and bronchoalveolar lavage in childhood-onset, complicated plastic bronchitis.

100 assays100 μg200ug100ug Lyophilized100 μg1 ml100ug100ug2ug25 1 mL1 Set

Related Pathways

paperclip

#32770741   2020/08/08 To Up

Bayesian latent class models to estimate diagnostic test accuracies of COVID-19 tests.

With great interest we read the article from Dramé et al. 1 "Should RT-PC be considered as gold standard in the diagnosis of Covid-19" questioning the conclusions from Cassaniti et al. . We agree with the argument that considering RT-PCR as gold standard when evaluating a new test will inevitably lead to biased test accuracy estimates of the new test . This article is protected by copyright. All rights reserved.
Sonja Hartnack, Paolo Eusebi, Polychronis Kostoulas

2907 related Products with: Bayesian latent class models to estimate diagnostic test accuracies of COVID-19 tests.

96 Tests n100 TESTS1 kit100 TESTS430 Tests / Kit100 TESTS600 Tests / Kit96 tests96 Tests n100 TESTS430 tests96 Tests n

Related Pathways

    No related Items
paperclip

#32770738   2020/08/08 To Up

Clinical and Radiological Diagnosis of Non-SARS-CoV-2 Viruses in the Era of Covid-19 Pandemic.

Following the announcement of first coronavirus disease 2019 (COVID-19) case on March 11, 2020, in Turkey we aimed to report the co-infection rates, and the clinical, laboratory, radiological distinctive features of viral pneumonia caused by viruses other than severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Aylin Ozgen Alpaydin, Naciye Sinem Gezer, Gokçen Omeroğlu Simsek, Kemal Can Tertemiz, Oya Ozlem Eren Kutsoylu, Arzu Nazli Zeka, Irmak Guzel, Mujde Soyturk, Ayca Arzu Sayiner, Vildan Avkan Oguz

1022 related Products with: Clinical and Radiological Diagnosis of Non-SARS-CoV-2 Viruses in the Era of Covid-19 Pandemic.

50 mg10 mg

Related Pathways

paperclip

#32770691   2020/08/08 To Up

Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19.

The management of critically ill patients with coronavirus disease 2019 (COVID-19), caused by a new human virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is challenging. Recently, there have been several reports with inconsistent results after treatment with convalescent plasma (CP) on critically ill patients with COVID-19, which was produced with a neutralizing antibody titer and tested in a P3 or P4 laboratory. However, due to the limitation of the conditions on mass production of plasma, most producers hardly had the capability to isolate the neutralizing antibody. Here, we report the clinical courses of three critically ill patients with COVID-19 receiving CP treatments by total immunoglobulin G (IgG) titer collection.
Miao Liu, Zhen Chen, Meng-Yuan Dai, Jun-Hui Yang, Xiao-Bing Chen, Di Chen, Hua You, Xin Guo, Yan Leng, Li Yu, Meng-Li Zhang, Xian Wu, Junyu Yang, Chong Gao, Daniel G Tenen, Li Chai, Fen Ai

1279 related Products with: Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19.

10 μg50 ml96T

Related Pathways